Researchmoz presents this most up-to-date research on"Research Report on Chinas Haemophilus Influenza B (HIB) Vaccine Industry, 2013-2017 Market, Trends, Share, Size Research Report".The
report focuses primarily on quantitative market metrics in order to
characterize the growth and evolution of the Remote Patient Monitoring
Market.
Haemophilus
influenza type B is a kind of haemophilus influenza with extremely
strong invasiveness. Among all the serious infections caused by
haemophilus influenzas, almost 90% were caused by haemophilus influenza
type B.
According
to the researches in recent years, HIB has become the first bacteria
that will cause diseases on the respiratory tracts of children in
China. It mainly causes lower respiratory infection and pneumonia.
After infected by HIB, the risk of getting invasive diseases is related
to one's HIB immune level. The prevalence rate of HIB antibody in
infants is quite high, which mainly comes from mothers.
Antibody
titer reaches the highest point when infants are three to four months
old. In addition, because infants are naturally exposed to HIB or other
pathogenic bacteria, their antibody concentration will gradually
increase in the early time. As a result, the incidence rate of HIB
invasive diseases is quite low among newborns. However, along with the
decline of antibody concentration, the incidence rate reaches the
highest point in the middle childhood.
In
addition, the incidence rate gradually declines with immune system
becoming increasingly complete. Therefore, HIB infection generally
happens on children below five years old. More specifically, the
incidence mainly happens to children below two years old. The
distribution of HIB infection seasons shows a double-peak in winter and
autumn as one peak and spring as the other peak. Generally speaking,
the incidence rate is the highest in winter and the lowest in summer.
Browse All Related Reports At : http://www.researchmoz.us/vaccines-market-reports-79.html
At
present, there is still no national statistical data on HIB diseases
in China. According to a large-scale epidemiology investigation held in
Hefei, the incidence rate of HIB meningitis was 107/100,000,000 among
children below five years old in Hefei and the fatality rate was 9.7%.
After treated, 21.4% survival children still suffer nervous or nervous
system complications or sequelae. According to the epidemiology
investigation in Hefei, CRI predicts that the incidence rate of HIB
invasive meningitis is 104/100,000,000 among children below five years
old. However, the incidence rate of HIB diseases among all people is
still not clear.
HIB
vaccines still belong to Vaccine II in China, so children are
inoculated HIB vaccines at the expenses of their parents voluntarily.
In 2012, China's lot release volume of HIB vaccines was 32.4098 million
doses, increasing by 34.84% YOY, with the market scale exceeding CNY 2
billion.
As
free vaccines that are widely applied in developed countries, HIB
vaccines have extremely huge development space in China. CRI predicts
that HIB vaccines are likely to become Vaccine I in the coming years.
Through this report, readers can acquire the following information:
- Development environment of China HIB vaccine industry
- Epidemic situation of HIB diseases in China
- Supply and demand of HIB vaccines in China
- Major manufacturing enterprises in China HIB vaccine market
Forecast on China HIB vaccine market, 2013-2017
The following enterprises and people are proposed to purchase this report:
- Vaccine manufacturing enterprises
- Medical institutions
- Investors and research institutes concerned about China vaccine industry
Contact Us:
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
http://www.researchmoz.us/
www.linkedin.com/company/researchmoz
https://twitter.com/researchmoz
https://www.facebook.com/pages/ResearchMoz/267379433319976
Blog: http://researchmoz.blogspot.com
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
http://www.researchmoz.us/
www.linkedin.com/company/researchmoz
https://twitter.com/researchmoz
https://www.facebook.com/pages/ResearchMoz/267379433319976
Blog: http://researchmoz.blogspot.com
No comments:
Post a Comment